Fulcrum Therapeutics (NASDAQ:FULC) Readies Phase 3 Candidate With Blockbuster Potential
Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald
Fulcrum Therapeutics Initiated at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Initiates Coverage On Fulcrum Therapeutics With Overweight Rating, Announces Price Target of $23
Buy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug Prospects
Express News | Fulcrum Therapeutics Inc. : Oppenheimer Cuts Target Price to $14 From $16
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target Is $15
Fulcrum Therapeutics (FULC) has an average rating of outperform and price targets ranging from $5 to $19, according to analysts polled by Capital IQ. Price: 7.80, Change: +0.45, Percent Change: +6.12
Express News | HC Wainwright & Co. Reiterates Buy on Fulcrum Therapeutics, Maintains $17 Price Target
Buy Rating Affirmed for Fulcrum Therapeutics: Licensing Deal With Sanofi and Promising Phase 3 Study
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Fulcrum Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Fulcrum Therapeutics, Lowers Price Target to $14
Fulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Express News | Fulcrum Therapeutics Inc : Leerink Partners Raises Target Price to $16 From $14
Fulcrum Upgraded by Goldman Sachs Ahead of Phase 3 Data
INFN, VYGR and AMSC Are Among After Hour Movers
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Fulcrum Therapeutics Raised to Buy From Neutral by Goldman Sachs
Express News | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy, Announces $15 Price Target
Fulcrum Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 87.5% Goldman Sachs → $15 Upgrades Neutral → Buy 03/13/2024 75% RBC Capital → $14 Initiates Cov
Buy Rating Upheld for Fulcrum Therapeutics Amid Sanofi Partnership and Upcoming Trial Catalysts
Earnings Call Summary | Fulcrum Therapeutics(FULC.US) Q1 2024 Earnings Conference
The following is a summary of the Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript:Financial Performance:Fulcrum Therapeutics reported a net loss of $26.9 million for Q1 2024, compar
Sanofi Gains License for Ex-U.S. Rights to Fulcrum Muscular Dystrophy Candidate